An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
The BBV152 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the efficacy, safety, and immunogenicity of BBV152 to prevent COVID-19 for up to 1 year after the second dose of BBV152.
Epistemonikos ID: 1f2b1743e007a1e7e7a22009c5b2213f954b5eb0
First added on: Nov 24, 2020